<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">20301577</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK1403</ArticleId></ArticleIdList><Book><Publisher><PublisherName>University of Washington, Seattle</PublisherName><PublisherLocation>Seattle (WA)</PublisherLocation></Publisher><BookTitle book="gene">GeneReviews<sup>&#xae;</sup></BookTitle><PubDate><Year>1993</Year></PubDate><BeginningDate><Year>1993</Year></BeginningDate><EndingDate><Year>2025</Year></EndingDate><AuthorList Type="editors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Adam</LastName><ForeName>Margaret P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Jerry</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mirzaa</LastName><ForeName>Ghayda M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Pagon</LastName><ForeName>Roberta A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Stephanie E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Amemiya</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author></AuthorList><Medium>Internet</Medium></Book><ArticleTitle book="gene" part="timothy"><i>CACNA1C</i>-Related Disorders</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Napolitano</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri;, Department of Molecular Medicine, University of Pavia, Pavia, Italy</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart)</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Priori</LastName><ForeName>Silvia G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri;, Department of Molecular Medicine, University of Pavia, Pavia, Italy</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText Label="CLINICAL CHARACTERISTICS">The clinical manifestations of <i>CACNA1C</i>-related disorders include a spectrum of nonsyndromic and syndromic phenotypes, which generally correlate with the impact of the pathogenic variant on calcium current. Phenotypes can include nonsyndromic long QT syndrome (rate-corrected QT [QTc] interval &gt;480 ms); nonsyndromic short QT syndrome (QTc &lt;350 ms), with risk of sudden death; Brugada syndrome (ST segment elevation in right precordial leads [V1-V2]) with short QT interval; classic Timothy syndrome (prolonged QT interval, autism, and congenital heart defect) with or without unilateral or bilateral cutaneous syndactyly variably involving fingers two (index), three (middle), four (ring), and five (little) and bilateral cutaneous syndactyly of toes two and three; and <i>CACNA1C</i>-related neurodevelopmental disorder, in which the features tend to favor one or more of the following: developmental delay&#xa0;/ intellectual disability, hypotonia, epilepsy, and/or ataxia.</AbstractText><AbstractText Label="DIAGNOSIS/TESTING">The diagnosis of a <i>CACNA1C</i>-related disorder is established in a proband with suggestive findings and a heterozygous pathogenic variant in <i>CACNA1C</i> identified by molecular genetic testing.</AbstractText><AbstractText Label="MANAGEMENT"><i>Treatment of manifestations:</i> Beta-blockers (nadolol preferred) and mexiletine may be used for prolonged QT interval; pacemaker placement&#xa0;/ temporary pacing for bradycardia with 2:1 atrioventricular block; quinidine for short QT syndrome and Brugada syndrome; consideration of catheter ablation for symptomatic Brugada syndrome; implantable cardioverter defibrillator (ICD) as soon as body weight allows for those with tachyarrhythmias; feeding therapy with low threshold for clinical feeding evaluation and/or radiographic swallowing study for dysphagia; consideration of gastrostomy tube placement for persistent feeding issues; standard treatment for congenital heart defects, developmental delay&#xa0;/ intellectual disability, epilepsy, ataxia, hypoglycemia, recurrent infections, and syndactyly. <i>Prevention of primary manifestations:</i> Arrhythmias must be prevented with the standard therapy, which may include medications, placement of an ICD, and/or ablation. Any surgical intervention must be performed under close cardiac monitoring, as anesthesia is a known trigger for cardiac arrhythmia in individuals with a <i>CACNA1C</i>-related disorder; fever can also be a trigger for arrhythmias in individuals with <i>CACNA1C</i>-related Brugada syndrome and requires aggressive treatment with standard antipyretic drugs. <i>Surveillance:</i> At each visit, measure growth parameters and evaluate nutritional safety of oral intake; assess mobility and self-help skills; monitor developmental progress and educational needs; assess for behavioral issues; assess for new manifestations such as seizures, changes in tone, and movement disorders; monitor for signs/symptoms of hypoglycemia; and monitor for recurrent infections. Every 6-12 months, follow-up evaluations with a cardiologist to include EKG, Holter, &amp; echocardiogram; monitor those with seizures as clinically indicated. Every 12 months, if remote device monitoring is available: evaluate persons with a pacemaker or ICD. <i>Agents/circumstances to avoid:</i> All drugs reported to prolong QT interval (see CredibleMeds<sup>&#xae;</sup>); drugs and dietary practices that could lead to hypoglycemia. <i>Evaluation of relatives at risk:</i> It is appropriate to clarify the genetic status of the older and younger at-risk relatives of a proband in order to identify as early as possible those who would benefit from a complete cardiac evaluation, institution of measures to prevent cardiac arrhythmias, and awareness of agents/circumstances to avoid. Predictive genetic testing is recommended for all at-risk family members of all ages from birth onward. While predictive genetic testing can be used to identify relatives who are heterozygous for a familial <i>CACNA1C</i> pathogenic variant and at risk for <i>CACNA1C</i>-related cardiac arrhythmias, it cannot be used to predict disease course (i.e., whether <i>CACNA1C</i>-related EKG changes and symptoms will occur and, if so, the age of onset and severity). <i>Pregnancy management:</i> Nadolol (the beta-blocker of choice for individuals with long QT syndrome in general) has not been associated with an increased risk above the general population risk of congenital anomalies in humans. Quinidine for short QT syndrome is also a preferred drug for use as an antiarrhythmic during human pregnancy and has not been associated with adverse fetal effects. Fetuses at risk of being affected with a <i>CACNA1C</i>-related disorder should be monitored for bradycardia and heart rate abnormalities that can be a sign of fetal arrhythmias.</AbstractText><AbstractText Label="GENETIC COUNSELING"><i>CACNA1C</i>-related disorders are inherited in an autosomal dominant manner. Many individuals diagnosed with a <i>CACNA1C</i>-related disorder &#x2013; particularly those individuals with a syndromic <i>CACNA1C</i>-related disorder (Timothy syndrome or <i>CACNA1C</i>-related neurodevelopmental syndrome) &#x2013; have the disorder as the result of a <i>de novo</i> pathogenic variant. Some individuals diagnosed with a <i>CACNA1C</i>-related disorder inherited the <i>CACNA1C</i> pathogenic variant from a heterozygous or mosaic parent. If a parent of the proband is affected and/or is known to be heterozygous for the pathogenic variant identified in the proband, the risk to the sibs of inheriting the pathogenic variant is 50%. If the proband has a known <i>CACNA1C</i> pathogenic variant that cannot be detected in the leukocyte DNA of either parent, the recurrence risk to sibs is greater than that of the general population because of the possibility of parental gonadal mosaicism. Once the <i>CACNA1C</i> pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing for a pregnancy at increased risk for a <i>CACNA1C</i>-related disorder are possible.</AbstractText><CopyrightInformation>Copyright &#xa9; 1993-2025, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="gene" part="timothy" sec="timothy.Summary">Summary</SectionTitle></Section><Section><SectionTitle book="gene" part="timothy" sec="timothy.GeneReview_Scope"><i>GeneReview</i> Scope</SectionTitle></Section><Section><SectionTitle book="gene" part="timothy" sec="timothy.Diagnosis">Diagnosis</SectionTitle></Section><Section><SectionTitle book="gene" part="timothy" sec="timothy.Clinical_Characteristics">Clinical Characteristics</SectionTitle></Section><Section><SectionTitle book="gene" part="timothy" sec="timothy.Genetically_Related_Allelic_Diso">Genetically Related (Allelic) Disorders</SectionTitle></Section><Section><SectionTitle book="gene" part="timothy" sec="timothy.Differential_Diagnosis">Differential Diagnosis</SectionTitle></Section><Section><SectionTitle book="gene" part="timothy" sec="timothy.Management">Management</SectionTitle></Section><Section><SectionTitle book="gene" part="timothy" sec="timothy.Genetic_Counseling">Genetic Counseling</SectionTitle></Section><Section><SectionTitle book="gene" part="timothy" sec="timothy.Resources">Resources</SectionTitle></Section><Section><SectionTitle book="gene" part="timothy" sec="timothy.Molecular_Genetics">Molecular Genetics</SectionTitle></Section><Section><SectionTitle book="gene" part="timothy" sec="timothy.Chapter_Notes">Chapter Notes</SectionTitle></Section><Section><SectionTitle book="gene" part="timothy" sec="timothy.References">References</SectionTitle></Section></Sections><KeywordList Owner="NLM"><Keyword MajorTopicYN="N">Timothy Syndrome</Keyword><Keyword MajorTopicYN="N">Timothy Syndrome</Keyword><Keyword MajorTopicYN="N">CACNA1C-Related Neurodevelopmental Syndrome</Keyword><Keyword MajorTopicYN="N">CACNA1C-Related Nonsyndromic Long QT Syndrome</Keyword><Keyword MajorTopicYN="N">CACNA1C-Related Nonsyndromic Short QT Syndrome</Keyword><Keyword MajorTopicYN="N">CACNA1C-Related Brugada Syndrome with Short QT</Keyword><Keyword MajorTopicYN="N">Voltage-dependent L-type calcium channel subunit alpha-1C</Keyword><Keyword MajorTopicYN="N">CACNA1C</Keyword><Keyword MajorTopicYN="N">CACNA1C-Related Disorders</Keyword></KeywordList><ContributionDate><Year>2006</Year><Month>2</Month><Day>15</Day></ContributionDate><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><ReferenceList><Reference><Citation>Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72:e91-e220.</Citation><ArticleIdList><ArticleId IdType="pubmed">29097296</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsuta Y, Tomizawa RR, Levin M, Tabin CJ. L-type voltage-gated Ca(2+) channel CaV1.2 regulates chondrogenesis during limb development. Proc Natl Acad Sci U S A. 2019;116:21592-601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6815189</ArticleId><ArticleId IdType="pubmed">31591237</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena MT, Espinosa-Rosales FJ, Hammarstr&#xf6;m L, Nonoyama S, Quinti I, Routes JM, Tang ML, Warnatz K. International Consensus Document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4:38-59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869529</ArticleId><ArticleId IdType="pubmed">26563668</ArticleId></ArticleIdList></Reference><Reference><Citation>Borlot F, Regan BM, Bassett AS, Stavropoulos DJ, Andrade DM. Prevalence of pathogenic copy number variation in adults with pediatric-onset epilepsy and intellectual disability. JAMA Neurol. 2017;74:1301-11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710585</ArticleId><ArticleId IdType="pubmed">28846756</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozarth X, Dines JN, Qian C, Mirzaa GM, Foss K, Lawrence Merritt J 2nd, Thies J, Mefford HC, Novotny E. Expanding clinical phenotype in CACNA1C related disorders: from neonatal onset severe epileptic encephalopathy to late-onset epilepsy. Am J Med Genet A. 2018;176:2733-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6312477</ArticleId><ArticleId IdType="pubmed">30513141</ArticleId></ArticleIdList></Reference><Reference><Citation>Burashnikov E, Pfeiffer R, Barajas-Martinez H, Delpon E, Hu D, Desai M, Borggrefe M, Haissaguerre M, Kanter R, Pollevick GD, Guerchicoff A, Laino R, Marieb M, Nademanee K, Nam GB, Robles R, Schimpf R, Stapleton DD, Viskin S, Winters S, Wolpert C, Zimmern S, Veltmann C, Antzelevitch C. Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm. 2010;7:1872-82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2999985</ArticleId><ArticleId IdType="pubmed">20817017</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriano L, Piscopo R, Aiello C, Novelli A, Iolascon A, Piscopo C. Expanding the phenotype of the CACNA1C-associated neurological disorders in children: systematic literature review and description of a novel mutation. Children (Basel). 2024;11:541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11119747</ArticleId><ArticleId IdType="pubmed">38790536</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufendach KA, Timothy K, Ackerman MJ, Blevins B, Pflaumer A, Etheridge S, Perry J, Blom NA, Temple J, Chowdhury D, Skinner JR, Johnsrude C, Bratincsak A, Bos JM, Shah M. Clinical outcomes and modes of death in Timothy syndrome: a multicenter international study of a rare disorder. JACC Clin Electrophysiol. 2018;4:459-66.</Citation><ArticleIdList><ArticleId IdType="pubmed">30067485</ArticleId></ArticleIdList></Reference><Reference><Citation>Endres D, Decher N, R&#xf6;hr I, Vowinkel K, Domschke K, Komlosi K, Tzschach A, Gl&#xe4;ser B, Schiele MA, Runge K, S&#xfc;&#xdf; P, Schuchardt F, Nickel K, Stallmeyer B, Rinn&#xe9; S, Schulze-Bahr E, Tebartz van Elst L. New Cav1.2 channelopathy with high-functioning autism, affective disorder, severe dental enamel defects, a short QT interval, and a novel CACNA1C loss-of-function mutation. Int J Mol Sci. 2020;21:8611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7696251</ArticleId><ArticleId IdType="pubmed">33203140</ArticleId></ArticleIdList></Reference><Reference><Citation>Etheridge SP, Bowles NE, Arrington CB, Pilcher T, Rope A, Wilde AA, Alders M, Saarel EV, Tavernier R, Timothy KW, Tristani-Firouzi M. Somatic mosaicism contributes to phenotypic variation in Timothy syndrome. Am J Med Genet A. 2011;155A:2578-83.</Citation><ArticleIdList><ArticleId IdType="pubmed">21910241</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuyama M, Wang Q, Kato K, Ohno S, Ding WG, Toyoda F, Itoh H, Kimura H, Makiyama T, Ito M, Matsuura H, Horie M. Long QT syndrome type 8: novel CACNA1C mutations causing QT prolongation and variant phenotypes. Europace. 2014;16:1828-37.</Citation><ArticleIdList><ArticleId IdType="pubmed">24728418</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillis J, Burashnikov E, Antzelevitch C, Blaser S, Gross G, Turner L, Babul-Hirji R, Chitayat D. Long QT, syndactyly, joint contractures, stroke and novel CACNA1C mutation: expanding the spectrum of Timothy syndrome. Am J Med Genet A. 2012;158A:182-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319791</ArticleId><ArticleId IdType="pubmed">22106044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzanti A, Underwood K, Nevelev D, Kofman S, Priori SG. The new kids on the block of arrhythmogenic disorders: short QT syndrome and early repolarization. J Cardiovasc Electrophysiol. 2017;28:1226-36.</Citation><ArticleIdList><ArticleId IdType="pubmed">28569435</ArticleId></ArticleIdList></Reference><Reference><Citation>Mio C, Passon N, Baldan F, Bregant E, Monaco E, Mancini L, Demori E, Damante G. CACNA1C haploinsufficiency accounts for the common features of interstitial 12p13.33 deletion carriers. Eur J Med Genet. 2020;63:103843.</Citation><ArticleIdList><ArticleId IdType="pubmed">31953239</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano C, Antzelevitch C. Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac voltage-dependent L-type calcium channel. Circ Res. 2011;108:607-18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056572</ArticleId><ArticleId IdType="pubmed">21372292</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano C, Mazzanti A, Porta-Sanchez A, Priori SG. Timothy Syndrome. In: Jalife J, Stevenson WG, eds. <i>Zipes and Jalife&#x2019;s Cardiac Electrophysiology: From Cell to Bedside</i>. 8 ed. Philadelphia, PA: Elsevier; 2021:1136-1145</Citation></Reference><Reference><Citation>Pan JY, Yuan S, Yu T, Su CL, Liu XL, He J, Li H. Regulation of L-type Ca2+ channel activity and insulin secretion by huntingtin-associated protein 1. J Biol Chem. 2016;291:26352-63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5159497</ArticleId><ArticleId IdType="pubmed">27624941</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagiotakos G, Haveles C, Arjun A, Petrova R, Rana A, Portmann T, Pasca SP, Palmer TD, Dolmetsch RE. Aberrant calcium channel splicing drives defects in cortical differentiation in Timothy syndrome. Elife. 2019;8:e51037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6964969</ArticleId><ArticleId IdType="pubmed">31868578</ArticleId></ArticleIdList></Reference><Reference><Citation>Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793-867.</Citation><ArticleIdList><ArticleId IdType="pubmed">26320108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran KV, Hennessey JA, Barnett AS, Yin X, Stadt HA, Foster E, Shah RA, Yazawa M, Dolmetsch RE, Kirby ML, Pitt GS. Calcium influx through L-type CaV1.2 Ca2+ channels regulates mandibular development. J Clin Invest. 2013;123:1638-46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613930</ArticleId><ArticleId IdType="pubmed">23549079</ArticleId></ArticleIdList></Reference><Reference><Citation>Raschwitz LS, El-Battrawy I, Schlentrich K, Besler J, Veith M, Roterberg G, Liebe V, Schimpf R, Lang S, Wolpert C, Zhou X, Akin I, Borggrefe M. Differences in short QT syndrome subtypes: a systematic literature review and pooled analysis. Front Genet. 2020;10:1312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6979065</ArticleId><ArticleId IdType="pubmed">32010184</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodan LH, Spillmann RC, Kurata HT, Lamothe SM, Maghera J, Jamra RA, Alkelai A, Antonarakis SE, Atallah I, Bar-Yosef O, Bilan F, Bjorgo K, Blanc X, Van Bogaert P, Bolkier Y, Burrage LC, Christ BU, Granadillo JL, Dickson P, Donald KA, Dubourg C, Eliyahu A, Emrick L, Engleman K, Gonfiantini MV, Good JM, Kalser J, Kloeckner C, Lachmeijer G, Macchiaiolo M, Nicita F, Odent S, O'Heir E, Ortiz-Gonzalez X, Pacio-Miguez M, Palomares-Bralo M, Pena L, Platzer K, Quinodoz M, Ranza E, Rosenfeld JA, Roulet-Perez E, Santani A, Santos-Simarro F, Pode-Shakked B, Skraban C, Slaugh R, Superti-Furga A, Thiffault I, van Jaabrsveld RH, Vincent M, Wang HG, Zacher P, Rush E, Pitt GS, Au PYB, Shashi V, et al. Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations. Genet Med. 2021;23:1922-32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8488020</ArticleId><ArticleId IdType="pubmed">34163037</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooryck C, Stef M, Burgelin I, Simon D, Souakri N, Thambo JB, Chateil JF, Lacombe D, Arveiler B. 2.3 Mb terminal deletion in 12p13.33 associated with oculoauriculovertebral spectrum and evaluation of WNT5B as a candidate gene. Eur J Med Genet. 2009;52:446-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19733267</ArticleId></ArticleIdList></Reference><Reference><Citation>Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, Sanguinetti MC, Keating MT. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci U S A. 2005;102:8089-96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1149428</ArticleId><ArticleId IdType="pubmed">15863612</ArticleId></ArticleIdList></Reference><Reference><Citation>Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, Napolitano C, Schwartz PJ, Joseph RM, Condouris K, Tager-Flusberg H, Priori SG, Sanguinetti MC, Keating MT. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004;119:19-31.</Citation><ArticleIdList><ArticleId IdType="pubmed">15454078</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenson PD, Mort M, Ball EV, Chapman M, Evans K, Azevedo L, Hayden M, Heywood S, Millar DS, Phillips AD, Cooper DN. The Human Gene Mutation Database (HGMD&#xae;): optimizing its use in a clinical diagnostic or research setting. Hum Genet. 2020;139:1197-207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7497289</ArticleId><ArticleId IdType="pubmed">32596782</ArticleId></ArticleIdList></Reference><Reference><Citation>Templin C, Ghadri JR, Rougier JS, Baumer A, Kaplan V, Albesa M, Sticht H, Rauch A, Puleo C, Hu D, Barajas-Martinez H, Antzelevitch C, Luscher TF, Abriel H, Duru F. Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J. 2011;32:1077-88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086900</ArticleId><ArticleId IdType="pubmed">21383000</ArticleId></ArticleIdList></Reference><Reference><Citation>Timothy KW, Bauer R, Larkin KA, Walsh EP, Abrams DJ, Gonzalez Corcia C, Valsamakis A, Pitt GS, Dick IE, Golden A. A natural history study of Timothy syndrome. Orphanet J Rare Dis. 2024;19:433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11585941</ArticleId><ArticleId IdType="pubmed">39580446</ArticleId></ArticleIdList></Reference><Reference><Citation>Wemh&#xf6;ner K, Friedrich C, Stallmeyer B, Coffey AJ, Grace A, Zumhagen S, Seebohm G, Ortiz-Bonnin B, Rinn&#xe9; S, Sachse FB, Schulze-Bahr E, Decher N. Gain-of-function mutations in the calcium channel CACNA1C (Cav1.2) cause non-syndromic long-QT but not Timothy syndrome. J Mol Cell Cardiol. 2015;80:186-95.</Citation><ArticleIdList><ArticleId IdType="pubmed">25633834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilde AAM, Semsarian C, M&#xe1;rquez MF, Sepehri Shamloo A, Ackerman MJ, Ashley EA, Sternick EB, Barajas-Martinez H, Behr ER, Bezzina CR, Breckpot J, Charron P, Chockalingam P, Crotti L, Gollob MH, Lubitz S, Makita N, Ohno S, Ortiz-Genga M, Sacilotto L, Schulze-Bahr E, Shimizu W, Sotoodehnia N, Tadros R, Ware JS, Winlaw DS, Kaufman ES; Document Reviewers; Aiba T, Bollmann A, Choi JI, Dalal A, Darrieux F, Giudicessi J, Guerchicoff M, Hong K, Krahn AD, MacIntyre C, Mackall JA, Mont L, Napolitano C, Ochoa JP, Peichl P, Pereira AC, Schwartz PJ, Skinner J, Stellbrink C, Tfelt-Hansen J, Deneke T. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm. 2022;19:e1-e60.</Citation><ArticleIdList><ArticleId IdType="pubmed">35390533</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><History><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20301577</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>